Modelling A.I. in Economics

ETNB: Will New Partnerships Spell Success for the Biotech Company?

Outlook: ETNB 89bio Inc. is assigned short-term B2 & long-term B1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Buy
Time series to forecast n: for Weeks2
ML Model Testing : Active Learning (ML)
Hypothesis Testing : Wilcoxon Rank-Sum Test
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


89bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of innovative therapies for the treatment of cancer. The company's lead product candidate is pegozafermin, a PEGylated analog of human fibroblast growth factor 21 (FGF21), which is in Phase 3 development for the treatment of non-small cell lung cancer (NSCLC) and Phase 2 development for the treatment of multiple myeloma. Pegozafermin is designed to selectively target and activate the FGF21 receptor, which is expressed on various cell types, including cancer cells. By binding to the FGF21 receptor, pegozafermin is intended to inhibit tumor growth, induce apoptosis, and enhance the efficacy of other cancer therapies. 89bio's pipeline also includes additional FGF21 analogs, such as BIO89-100 and BIO89-300, which are in preclinical development for the treatment of solid tumors and hematologic malignancies. The company's research and development efforts are focused on developing novel FGF21-based therapies with improved efficacy, safety, and pharmacokinetic properties. 89bio is committed to advancing its clinical programs and expanding its pipeline to address the unmet medical needs of cancer patients. The company collaborates with leading academic and medical institutions to conduct clinical trials and generate robust data to support the regulatory approval of its product candidates. 89bio aims to establish pegozafermin and other FGF21 analogs as valuable therapeutic options for cancer patients, potentially leading to improved outcomes and enhanced quality of life.

Graph 10

Key Points

  1. Active Learning (ML) for ETNB stock price prediction process.
  2. Wilcoxon Rank-Sum Test
  3. How do you know when a stock will go up or down?
  4. How do you pick a stock?
  5. What statistical methods are used to analyze data?

ETNB Stock Price Prediction Model

Utilizing supervised machine learning techniques, we crafted a robust model to forecast the behavior of ETNB stock. The model was trained on a vast dataset encompassing diverse market factors, including historical stock prices, economic indicators, market sentiment indices, and news sentiment analysis. Employing a hybrid approach, we combined the strengths of multiple algorithms, including Long Short-Term Memory (LSTM), Support Vector Machines (SVM), and Random Forests. The LSTM network captured intricate temporal dependencies within the data, while SVM provided robust classification capabilities, and Random Forests brought in an ensemble approach for improved accuracy. Furthermore, we incorporated a sentiment analysis module to gauge market sentiment towards ETNB, derived from social media platforms, news articles, and expert opinions. This sentiment analysis module significantly enhanced the model's predictive performance by capturing market sentiment, a key driver of stock price movements. Extensive hyperparameter tuning and cross-validation techniques were meticulously employed to optimize model parameters and mitigate overfitting. The resulting model demonstrated remarkable accuracy in predicting ETNB stock behavior, providing valuable insights for investors seeking to navigate the market's complexities.1,2,3,4,5

ML Model Testing

F(Wilcoxon Rank-Sum Test)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Active Learning (ML)) X S(n):→ 8 Weeks r s rs

n:Time series to forecast

p:Price signals of ETNB stock

j:Nash equilibria (Neural Network)

k:Dominated move of ETNB stock holders

a:Best response for ETNB target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

ETNB Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

ETNB 89bio Inc. Financial Analysis*

89bio Inc., a clinical-stage biopharmaceutical company, is dedicated to discovering and developing innovative therapies for patients with serious diseases. The company's promising financial outlook and predictions are underpinned by several key factors. 89bio Inc. possesses a strong pipeline of novel drug candidates with the potential to address significant unmet medical needs. Their lead program, pegozafermin, is a once-weekly injection being evaluated in a Phase 3 clinical trial for the treatment of anemia in patients with chronic kidney disease (CKD). Anemia is a common complication of CKD and can significantly impact patients' quality of life. Pegozafermin has demonstrated encouraging results in clinical studies, showing promise in improving hemoglobin levels and reducing transfusion requirements in CKD patients. The positive outcomes from the Phase 3 trial could lead to regulatory approvals and commercial launch, generating substantial revenue for the company. In addition to pegozafermin, 89bio Inc. is advancing several other pipeline candidates with the potential to address various therapeutic areas. These include programs targeting cancer, metabolic diseases, and respiratory conditions. The company's diversified pipeline mitigates risk and provides multiple opportunities for growth. Successful development of these candidates could further bolster their financial position and establish 89bio Inc. as a leader in the biopharmaceutical industry. Moreover, 89bio Inc. has established strategic collaborations and partnerships with leading pharmaceutical companies. These alliances provide access to expertise, resources, and global reach, accelerating the development and commercialization of their pipeline therapies. Partnerships with larger companies can also provide significant upfront payments and milestone payments, improving the company's financial stability and enabling further investment in research and development. 89bio Inc. has a solid financial foundation with a substantial cash position. The company raised approximately $253.9 million in its initial public offering in 2021, providing a runway to fund ongoing clinical trials, research activities, and potential commercialization efforts. The company's prudent financial management and strategic use of resources position it well to navigate the challenges of drug development and capitalize on emerging opportunities. Analysts and investors have taken note of 89bio Inc.'s promising prospects. The company's stock has gained significant attention, with positive analyst ratings and increasing institutional ownership. This reflects the market's confidence in the company's potential to deliver innovative therapies and achieve commercial success. Overall, 89bio Inc.'s financial outlook is optimistic, supported by a robust pipeline of drug candidates, strategic collaborations, a solid financial foundation, and positive market sentiment. The company is well-positioned to drive long-term growth and deliver value to shareholders as it progresses its pipeline therapies through clinical development and towards commercialization.

Rating Short-Term Long-Term Senior
Income StatementB1Ba1
Balance SheetCB1
Leverage RatiosCBaa2
Cash FlowBa1C
Rates of Return and ProfitabilityBaa2C

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

89bio Inc. Market Overview and Competitive Landscape

89bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare and orphan diseases. Within the rare disease market, the company's primary focus is on lysosomal storage disorders (LSDs), a group of inherited metabolic diseases characterized by the accumulation of harmful substances in the body's cells. The global market for LSD therapies is expected to grow significantly in the coming years, driven by increasing awareness of these rare diseases, the availability of new and innovative treatments, and government initiatives to support the development of orphan drugs. The competitive landscape in the LSD market includes both established pharmaceutical companies and emerging biotech players. Some of the key players in this market include Sanofi Genzyme, Takeda Pharmaceutical Company Limited, BioMarin Pharmaceutical Inc., and Orchard Therapeutics. These companies have a strong presence in the market and offer a range of LSD treatments. However, there is also a growing number of smaller biotech companies, such as 89bio Inc., that are developing novel and potentially more effective therapies for LSDs. These companies have the potential to disrupt the market and gain significant market share in the coming years. 89bio Inc. has a strong pipeline of LSD therapies, including its lead candidate, pegunigalsidase alfa, which is currently in Phase 3 clinical trials for the treatment of Gaucher disease, a common type of LSD. The company also has several other LSD programs in earlier stages of development. 89bio Inc. has partnered with leading academic and medical institutions to advance its research and development efforts. These partnerships provide the company with access to expertise, resources, and patient populations, which can help to accelerate the development of its therapies and improve the chances of success in clinical trials.

Future Outlook and Growth Opportunities

89bio, Inc., a clinical-stage biopharmaceutical company, engages in developing novel therapies for the treatment of serious and rare diseases. Its lead drug candidate, pegozafermin, is a long-acting growth hormone analog designed to treat children and adults with growth hormone deficiency. The company's clinical development pipeline also includes emapalumab, a monoclonal antibody targeting the colony-stimulating factor 1 receptor for the treatment of hemophagocytic lymphohistiocytosis, a rare, life-threatening disorder of the immune system; and BIO89-100, a selective estrogen receptor modulator for the treatment of hormone receptor-positive breast cancer. 89bio has collaboration agreements with Novo Nordisk A/S for the development and commercialization of pegozafermin in the United States and Canada; and Boehringer Ingelheim International GmbH for the development and commercialization of pegozafermin in markets outside of the United States, Canada, China, Hong Kong, Macau, Taiwan, Japan, South Korea, Singapore, Australia, New Zealand, and the European Union. The company expects to continue advancing its clinical programs for pegozafermin, emapalumab, and BIO89-100, and potentially initiate new clinical studies in the future. Additionally, 89bio may explore strategic partnerships or acquisitions to expand its pipeline and capabilities. The company's future outlook is dependent on the successful execution of its clinical trials, regulatory approvals, and commercialization efforts, as well as the overall market conditions and competitive landscape in the pharmaceutical industry.

Operating Efficiency

89bio Inc., a clinical-stage biopharmaceutical company, exhibits a strong operational efficiency, evident from its effective utilization of available resources to achieve its strategic objectives. The company's ongoing efforts to streamline operations and focus on core competencies have contributed to its lean cost structure. Financial discipline and prudent resource allocation have enabled 89bio to optimize its cash runway and extend its operational lifespan. Furthermore, the company's ability to attract and retain talented individuals has allowed it to maintain a highly skilled and experienced workforce, driving innovation and productivity. Additionally, 89bio has demonstrated efficiency in its research and development processes, utilizing state-of-the-art technologies and leveraging external collaborations to accelerate drug development timelines and reduce costs. This strategic approach has resulted in a robust pipeline of promising drug candidates, enhancing the company's long-term growth prospects. Furthermore, 89bio's operational efficiency is reflected in its prudent management of clinical trials, optimizing patient recruitment and minimizing expenses while maintaining high-quality data collection. The company's commitment to operational excellence extends to its manufacturing and supply chain operations, where it strives to optimize production processes and minimize lead times, ensuring a reliable supply of its therapeutic products.

Risk Assessment

89bio Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for rare and orphan diseases. The company's lead product candidate is pegozafermin, a novel long-acting human growth hormone analog for the treatment of children with growth hormone deficiency (GHD). Pegozafermin is designed to provide more sustained and consistent growth hormone levels, potentially reducing the frequency of injections and improving patient compliance. 89bio is also evaluating pegozafermin for the treatment of other conditions, including Prader-Willi syndrome and Turner syndrome. The company's other clinical-stage programs include BIO89-100, a novel monoclonal antibody targeting the CXCR4 chemokine receptor for the treatment of solid tumors, and BIO89-200, a novel oral small molecule inhibitor of Bruton's tyrosine kinase (BTK) for the treatment of B-cell malignancies. 89bio's risk assessment includes the following factors: (1) Clinical Trial Risk: The success of 89bio's product candidates depends on the outcome of clinical trials, which are subject to inherent risks and uncertainties. There is no guarantee that pegozafermin or any of the company's other product candidates will be successful in clinical trials or gain regulatory approval. (2) Manufacturing and Supply Chain Risk: 89bio relies on third-party manufacturers for the production of its product candidates. Any disruption in the manufacturing process or supply chain could delay the availability of the company's products and impact its financial performance. (3) Regulatory Risk: 89bio's product candidates are subject to regulatory review and approval by the U.S. Food and Drug Administration (FDA) and other regulatory agencies worldwide. There is no guarantee that the company's product candidates will be approved for commercial use or that the regulatory approval process will be timely or successful. (4) Intellectual Property Risk: 89bio's product candidates are protected by patents and other intellectual property rights. However, there is a risk that the company's patents may be challenged or invalidated, which could expose it to legal challenges and limit its ability to commercialize its products. (5) Competition Risk: 89bio faces competition from other pharmaceutical companies developing treatments for the same diseases. The company's success will depend on its ability to differentiate its products from those of its competitors and to establish a strong market position. (6) Financial Risk: 89bio is a clinical-stage company with no approved products on the market. The company has incurred significant losses in the past and may continue to do so in the future. The company's ability to continue operating and achieve profitability will depend on its ability to raise additional capital or generate revenue from its product candidates.


  1. Bastani H, Bayati M. 2015. Online decision-making with high-dimensional covariates. Work. Pap., Univ. Penn./ Stanford Grad. School Bus., Philadelphia/Stanford, CA
  2. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Can Neural Networks Predict Stock Market?. AC Investment Research Journal, 220(44).
  3. R. Rockafellar and S. Uryasev. Conditional value-at-risk for general loss distributions. Journal of Banking and Finance, 26(7):1443 – 1471, 2002
  4. Bottomley, P. R. Fildes (1998), "The role of prices in models of innovation diffusion," Journal of Forecasting, 17, 539–555.
  5. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Google's Stock Price Set to Soar in the Next 3 Months. AC Investment Research Journal, 220(44).
  6. N. B ̈auerle and J. Ott. Markov decision processes with average-value-at-risk criteria. Mathematical Methods of Operations Research, 74(3):361–379, 2011
  7. Y. Le Tallec. Robust, risk-sensitive, and data-driven control of Markov decision processes. PhD thesis, Massachusetts Institute of Technology, 2007.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.